Therapeutic Asset Ratings

6,371 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Atezolizumab Hematopoietic And Lymphoid System Neoplasm	Cancer Research UK	P2/3	BB (64)
Blinatumomab Lymphoblastic Lymphoma	St. Jude Children's Research Hospital	P2/3	BB (64)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Of The Elderly	University of Washington	P2/3	BB (64)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER T-Cell/Histiocyte Rich Large B Cell Lymphoma	Ruijin Hospital	P2/3	BB (64)
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER Acute Lymphoblastic Leukemia	University of Birmingham	P2/3	BB (64)
Ipilimumab Gliosarcoma	University College, London	P2/3	BB (64)
Nivolumab Urinary Bladder Carcinoma	National Cancer Institute (NCI)	P2/3	BB (64)
Nivolumab Gliosarcoma	Andrew P. Groves	P2/3	BB (64)
Relatlimab Urethra Transitional Cell Carcinoma	National Cancer Institute (NCI)	P2/3	BB (64)
Relatlimab Muscle Invasive Ureter Urothelial Carcinoma	National Cancer Institute (NCI)	P2/3	BB (64)
Sugemalimab Small Cell Lung Carcinoma	Peking University Cancer Hospital & Institute	P2/3	BB (64)
TRASTUZUMAB Gallbladder Cancer	Cancer Research UK	P2/3	BB (64)
TRASTUZUMAB Hematopoietic And Lymphoid System Neoplasm	Cancer Research UK	P2/3	BB (64)
Atezolizumab Lung Cancer	University of Washington	P4	B (63)
Belimumab Sjogren Syndrome	Peking Union Medical College Hospital	P4	B (63)
Cetuximab Neoplasm	Mirati Therapeutics Inc.	P4	B (63)
Denosumab Metabolic Dysfunction-Associated Steatotic Liver Disease	Aristotle University Of Thessaloniki	P4	B (63)
Denosumab Postmenopausal Osteoporosis	Aristotle University Of Thessaloniki	P4	B (63)
Evolocumab Cardiovascular Disorder	Amgen	P4	B (63)
Evolocumab Myocardial Infarction	Amgen	P4	B (63)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER Hepatocellular Carcinoma	Riboscience, LLC.	P4	B (63)
Nivolumab Immunotherapy	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P4	B (63)
Nivolumab Locally Advanced	Centre Francois Baclesse	P4	B (63)
Nivolumab Surgery Programmed	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P4	B (63)
Pembrolizumab Colorectal Cancer	National Cancer Center Hospital East	P4	B (63)

Showing 551 to 575 of 6,371 assets

PreviousPage 23 of 255Next